Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus

TerminatedOBSERVATIONAL
Enrollment

678

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Linagliptin

tablet

Trial Locations (51)

Unknown

Boehringer Ingelheim Investigational Site 43, Agoo, La Union

Boehringer Ingelheim Investigational Site 40, Angeles City, Pampanga

Boehringer Ingelheim Investigational Site 31, Angono, Rizal

Boehringer Ingelheim Investigational Site 32, Antipolo, Rizal

Boehringer Ingelheim Investigational Site 27, Aparri, Cagayan

Boehringer Ingelheim Investigational Site 4, Batangas

Boehringer Ingelheim Investigational Site 48, Butuan City, Agusan Del Norte

Boehringer Ingelheim Investigational Site 12, Cabanatuan, Nueva Ecija

Boehringer Ingelheim Investigational Site 23, Cagayan de Oro

Boehringer Ingelheim Investigational Site 3, Caloocan

Boehringer Ingelheim Investigational Site 42, Cardona, Rizal

Boehringer Ingelheim Investigational Site 25, Cebu

Boehringer Ingelheim Investigational Site 44, Dagupan, Pangasinan

Boehringer Ingelheim Investigational Site 49, Iligan City, Lanao Del Norte

Boehringer Ingelheim Investigational Site 2, Iloilo City

Boehringer Ingelheim Investigational Site 45, Iriga City, Camarines Sur

Boehringer Ingelheim Investigational Site 20, Laoag, Ilocos Norte

Boehringer Ingelheim Investigational Site 24, Las Piñas

Boehringer Ingelheim Investigational Site 7, Legazpi, Albay

Boehringer Ingelheim Investigational Site 35, Lucena, Quezon

Boehringer Ingelheim Investigational Site 1, Makati

Boehringer Ingelheim Investigational Site 39, Malolos, Bulacan

Boehringer Ingelheim Investigational Site 37, Mandaluyong

Boehringer Ingelheim Investigational Site 28, Manila

Boehringer Ingelheim Investigational Site 5, Marikina City

Boehringer Ingelheim Investigational Site 16, Meycauyan, Bulacan

Boehringer Ingelheim Investigational Site 47, Naga City, Camarines Sur

Boehringer Ingelheim Investigational Site 15, Olongapo City

Boehringer Ingelheim Investigational Site 10, Pampanga

Boehringer Ingelheim Investigational Site 19, Paranaque City

Boehringer Ingelheim Investigational Site 51, Pasay

Boehringer Ingelheim Investigational Site 30, Pasig

Boehringer Ingelheim Investigational Site 34, Puerto Princesa, Palawan

Boehringer Ingelheim Investigational Site 26, Quezon City

Boehringer Ingelheim Investigational Site 11, Rosales, Pangasinan

Boehringer Ingelheim Investigational Site 21, San Fernando, La Union

Boehringer Ingelheim Investigational Site 9, San Fernando, Pampanga

Boehringer Ingelheim Investigational Site 13, San Jose, Nueva Ecija

Boehringer Ingelheim Investigational Site 29, San Juan City

Boehringer Ingelheim Investigational Site 8, San Pablo, Laguna

Boehringer Ingelheim Investigational Site 50, San Pedro, Laguna

Boehringer Ingelheim Investigational Site 41, Santiago City, Isabela

Boehringer Ingelheim Investigational Site 36, Sogod, Southern Leyte

Boehringer Ingelheim Investigational Site 38, Sta.Maria, Bulacan

Boehringer Ingelheim Investigational Site 6, Tacloban City

Boehringer Ingelheim Investigational Site 33, Tagbilaran, Bohol

Boehringer Ingelheim Investigational Site 14, Tuguegarao, Cagayan

Boehringer Ingelheim Investigational Site 18, Urdaneta, Pangasinan

Boehringer Ingelheim Investigational Site 46, Valencia City Bukidnon

Boehringer Ingelheim Investigational Site 17, Valenzuela, Bulacan

Boehringer Ingelheim Investigational Site 22, Zamboanga City

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01826370 - Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter